Long-Term Impact of Androgen-Deprivation Therapy on Cardiovascular Morbidity after Radiotherapy for Clinically Localized Prostate Cancer

To characterize the impact of androgen-deprivation therapy (ADT) on the incidence of cardiovascular events (CE) in prostate cancer patients treated with radiotherapy (RT).

2211 patients with localized prostate cancer were treated with RT from 1988-2008 at our institution. 991 patients (44. 8%) received ADT at the time of RT for a median of 6. 1 months. Salvage ADT was initiated prior to CE in 365 men (16. 5%) at a median of 5. 5 years (range, 0. 6 to 18. 4 years) after RT and continued for a median of 4. 3 years. A nomogram was constructed to predict the 10-year risk of CE post-RT.

Patients receiving ADT at the time of RT exhibited significantly higher 10-year incidence of CE (19. 6%, 95% CI 17. 0-22. 6%) than those not receiving ADT (14. 3%, 95% CI 12. 2%-16. 7%, P = . 005). On multivariate analysis, both ADT at the time of RT (P= . 007) and the time of salvage (P = . 0004) were associated with increased CE risk, as were advanced age (P = . 02), smoking (P = . 0007), history of diabetes (P = . 0007), and history of CE before RT (P < . 0001). A nomogram using patient age, smoking status, history of pre-RT CE, history of diabetes, and ADT use at the time of RT predicted the rate of 10-year CE with a C-index of 0. 81 (95% CI, 0. 72-0. 88).

While ADT is often an essential part of prostate-cancer treatment, patients should be counseled regarding increased risks of CE and prophylactic efforts should be considered to mitigate that risk.

Urology. 2015 Oct 14 [Epub ahead of print]

Zachary A Kohutek, Emily Steinberger, Xin Pei, Weiji Shi, Zhigang Zhang, Marisa A Kollmeier, Michael J Zelefsky

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. , Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. , Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. , Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. , Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. , Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. , Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: zelefskym@mskcc. org.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe